Gossamer bio to present preclinical data at the american thoracic society (ats) 2025 international conference

San diego--(business wire)---- $goss--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), today announced that the company will present a poster at the american thoracic society (ats) 2025 international conference, taking place from may 16th through 21st, in san francisco, califor.
GOSS Ratings Summary
GOSS Quant Ranking